Threshold halting enrollment in clinical trial

Redwood City biopharmaceutical firm Threshold Pharmaceuticals Inc. (THLD) will stop enrollment in a Phase 2 clinical trial evaluating the use of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The first stage of the trial, which included 21 patients, showed only one confirmed partial response. Under the design of the trial, three or more responses were required before an additional 29 patients would have been enrolled.

Patients already enrolled will be given the option to continue in the trial.

Just Posted

Mayor sets deadline to empty seismically unsafe jail, but city still lacks a plan to make it happen

On the 30th anniversary of the devastating Loma Prieta earthquake, Mayor London… Continue reading

E-scooter company Skip announces layoffs after losing SF permit

San Francisco-based e-scooter company Skip this week announced pending layoffs for roughly… Continue reading

SF files motion to dismiss NRA’s lawsuit over ‘domestic terrorist’ label

San Francisco filed a motion Thursday to dismiss the lawsuit filed against… Continue reading

Thirty years after Loma Prieta, is San Francisco ready for the next ‘big one?’

Bay Area residents breathed a sigh of relief this week after a… Continue reading

With Loftus set to take office, poll shows voters disapprove of last-minute DA appointment

Mayor London Breed made an unpopular decision when she named candidate Suzy… Continue reading

Most Read